NEW YORK (GenomeWeb News) – HTG Molecular Diagnostics said today that it has licensed exclusive rights from Vancouver's Centre of Excellence for the Prevention of Organ Failure (PROOF Centre) to commercialize gene expression tests for prognosis of COPD patients who will experience frequent lung attacks.

HTG Molecular Diagnostics said it plans to use the PROOF Centre's testing technology to develop an assay on its qNPA platform, and that the Centre will help to clinically validate the test in Canada.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Genome Research this week: mitochondrial and nuclear gene fusions in cancer, role of genomic imprinting in tissue-specific gene expression, and more.

Maria Freire from the Foundation for the NIH calls for "politically popular pledges of support" for the NIH to turn into support for increased funding for the agency.

A Thomson Reuters analysis indicates that the life sciences, rather than the tech sector, are increasingly driving global innovation.

The White House says ethical discussions about genome editing of the human germline are needed.